137 related articles for article (PubMed ID: 19009971)
1. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Scheen AJ; Paquot N; Lefebvre PJ
Rev Med Liege; 2008 Oct; 63(10):624-9. PubMed ID: 19009971
[TBL] [Abstract][Full Text] [Related]
2. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Neil HA; Matthews DR
N Engl J Med; 2008 Oct; 359(15):1565-76. PubMed ID: 18784091
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
5. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
Palmer AJ; Sendi PP; Spinas GA
Schweiz Med Wochenschr; 2000 Jul; 130(27-28):1034-40. PubMed ID: 10953853
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
8. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
10. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
Christiansen AL; Madsbad S
Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
[TBL] [Abstract][Full Text] [Related]
11. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
12. Implications of the United Kingdom prospective diabetes study.
Baldeweg SE; Yudkin JS
Prim Care; 1999 Dec; 26(4):809-27. PubMed ID: 10523461
[TBL] [Abstract][Full Text] [Related]
13. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
Bilous R
Diabet Med; 2008 Aug; 25 Suppl 2():25-9. PubMed ID: 18717975
[TBL] [Abstract][Full Text] [Related]
14. Management of type 2 diabetes: long-awaited evidence of benefits after blood sugar control.
Prescrire Int; 1999 Oct; 8(43):147-52. PubMed ID: 11503841
[TBL] [Abstract][Full Text] [Related]
15. [++UKPDS Study. Metformin in obese patients with Type 2 diabetes (UKPDS 340].
Janka HU
Internist (Berl); 2000 Jul; 41(7):688-9. PubMed ID: 10929259
[No Abstract] [Full Text] [Related]
16. [The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results].
Levy JC; Cull CA; Stratton IM; Holman RR; Turner RC
Journ Annu Diabetol Hotel Dieu; 1993; ():123-37. PubMed ID: 8331860
[No Abstract] [Full Text] [Related]
17. Improving survival with metformin: the evidence base today.
Scarpello JH
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S36-43. PubMed ID: 14502099
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
19. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
Jansson SP; Svärdsudd K; Andersson DK
Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
[TBL] [Abstract][Full Text] [Related]
20. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct].
MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
